BioScience Managers Limited

Acrux Limited is a pharmaceutical company based in West Melbourne, Australia, specializing in the development and commercialization of generic and specialty topical pharmaceuticals. Founded in 1998, Acrux focuses on innovative drug delivery systems that administer medications through the skin. Its product offerings include testosterone solutions for men with low testosterone levels, as well as estradiol sprays for women experiencing menopausal flushes, marketed under the Evamist and Lenzetto brand names. Acrux is advancing a diverse product pipeline aimed at treating hormonal deficiencies, pain, central nervous system disorders, and contraceptive needs. The company has completed numerous human clinical trials with its lead product, Evamist, nearing the end of a phase 3 trial in the United States. With a global presence across Australia, the United States, Germany, and other countries, Acrux aims to provide affordable and effective pharmaceutical solutions through its robust technical and clinical expertise.

Cynata Therapeutics Limited is an Australian company focused on developing and commercializing its proprietary Cymerus™ mesenchymal stem cell technology for therapeutic applications. The company’s lead product candidate, CYP-001, has completed Phase I clinical trials aimed at treating graft versus host disease. In addition to this, Cynata is exploring treatments for various conditions such as asthma, heart attack, diabetic wounds, coronary artery disease, and acute respiratory distress syndrome, among others, which are currently in preclinical stages. The Cymerus technology utilizes induced pluripotent stem cells (iPSCs) derived from adult donors, enabling the efficient and scalable production of mesenchymal stem cells. This innovative approach addresses existing limitations in stem cell manufacturing, allowing for virtually limitless quantities of therapeutic cells without the need for continuous donor sourcing. Cynata collaborates with several prestigious institutions, including Monash University and Massachusetts General Hospital, to advance its research and development efforts. Founded in 2011 and based in Carlton, Australia, Cynata is positioned to significantly contribute to the field of regenerative medicine.

Adherium Limited is a developer and manufacturer of digital health technologies focused on improving medication adherence in patients with chronic diseases. The company, founded in 2001 and headquartered in Auckland, New Zealand, offers Hailie, a solution specifically designed for asthma and COPD patients. Hailie includes Bluetooth-enabled sensors that attach to existing inhalers, capturing and transmitting usage data to patients' smartphones, complemented by a mobile app that allows users, caregivers, and healthcare professionals to track adherence, set reminders, and gain insights into medication usage. Adherium's solutions cater to a diverse range of stakeholders, including patients, pharmaceutical companies, healthcare providers, and contract research organizations. The company has established collaborations, such as with HGE Health, aimed at enhancing chronic obstructive pulmonary disease management.

We are a North American company, whose mission is to provide high quality medications for those patients who need them to treat their disease by making the medicine accessible to everyone. Our reason for being is to close the gap between pharmaceutical manufacturers and patients around the world whose quality of life depends on receiving the right treatment at the right place and time. At Pharmaxis Group we believe that working closely with our customers, employees, shareholders and key partners allows us to provide exceptional value in all the services we provide. Specialized in the supply of drugs that are difficult to find in the fields of oncological, immunological, orphan diseases among others. Our global network of pharmaceutical suppliers, combined with our strong logistics network, includes certified partners in good storage and handling practices, and good manufacturing practices, all necessary to properly guarantee high quality in all the products and services.

Canary Medical Inc. is a medical technology company based in Vancouver, Canada, founded in 2013. It specializes in the development and commercialization of patented implantable sensor technology designed for remote patient monitoring. The company has created devices such as the Canary Health Implantable Reporting Processor (CHIRP) and the canturio™te, the first "smart knee" tibial extension, which autonomously monitors patient activity and joint performance. These devices collect and transmit medical data to the cloud with minimal reliance on patient compliance or physician oversight. Canary Medical aims to transform healthcare by providing reliable and cost-effective data collection and analysis, thereby improving patient outcomes and reducing costs for healthcare providers. The company is backed by a team of seasoned entrepreneurs, researchers, and data scientists with expertise in medical device design and data informatics.

Immunosis is a biotech company focused on advancing genetic technologies for the early detection of Primary Immune Deficiency (PID). The company has developed a proprietary diagnostic test that utilizes genetic information to identify patients with PID, aiming to shorten the time needed for diagnosis. By facilitating timely care, Immunosis seeks to improve patient outcomes for individuals suffering from immune deficiency conditions, ultimately enhancing their recovery prospects.

Rex Bionics Ltd. is a New Zealand-based company that develops and manufactures advanced robotic medical devices aimed at rehabilitation for individuals with mobility impairments. Established in 2007, the company focuses on creating solutions to enhance the physical and psychological well-being of those affected by conditions such as spinal cord injuries, strokes, and other neurological traumas. Its primary product, the REX, is a hands-free, self-supporting robotic device designed to assist users in exercising, walking, and standing independently. Rex Bionics also offers the REX P model, intended for personal homecare applications. Through its innovative technology, Rex Bionics aims to improve the rehabilitation experience and outcomes for patients facing significant mobility challenges.

Rex Bionics Ltd. is a New Zealand-based company that develops and manufactures advanced robotic medical devices aimed at rehabilitation for individuals with mobility impairments. Established in 2007, the company focuses on creating solutions to enhance the physical and psychological well-being of those affected by conditions such as spinal cord injuries, strokes, and other neurological traumas. Its primary product, the REX, is a hands-free, self-supporting robotic device designed to assist users in exercising, walking, and standing independently. Rex Bionics also offers the REX P model, intended for personal homecare applications. Through its innovative technology, Rex Bionics aims to improve the rehabilitation experience and outcomes for patients facing significant mobility challenges.

Avita Medical Inc. is a commercial-stage regenerative tissue company headquartered in Valencia, California, specializing in innovative treatment solutions for burn injuries, chronic wounds, and dermatological conditions. The company leverages its proprietary technology to harness the regenerative properties of a patient’s own skin, with its lead product being the RECELL System. This device allows healthcare professionals to create a suspension of Spray-On Skin cells from a small sample of the patient's skin, facilitating the treatment of acute thermal burns in adults. Avita is currently focusing its efforts on the U.S. market, where the RECELL System is being rolled out across approximately 136 burn centers, while also exploring clinical trials for expanded indications, including pediatric applications and soft-tissue reconstruction. The company has established research collaborations with various institutions to advance its development initiatives, including potential treatments for conditions like epidermolysis bullosa and skin rejuvenation.

Saluda Medical Pty Ltd. is a medical device company specializing in the development of neuromodulation technologies for chronic neurological conditions. Founded in 2010 and based in Artarmon, Australia, with additional offices in the United States and the United Kingdom, Saluda Medical focuses on its innovative Evoke system. This investigational device employs a closed-loop spinal cord stimulation approach that continuously monitors the spinal cord's response to stimulation and adjusts treatment in real-time to optimize patient outcomes. By utilizing a unique dose-control platform, Saluda Medical aims to customize therapy based on individual neural responses, thereby improving the management of chronic pain, particularly in patients suffering from conditions such as neuropathic pain and chronic back pain.

HeartWare International, Inc. specializes in the development and manufacturing of small implantable heart pumps, also known as ventricular assist devices, aimed at treating advanced heart failure. The company offers the HeartWare Ventricular Assist System, which comprises a left ventricular assist device, patient accessories, and surgical tools designed to provide critical circulatory support for patients in the advanced stages of heart failure. Additionally, HeartWare is working on the Miniaturized Ventricular Assist Device, intended for chronic heart failure patients. The company markets its products through clinical studies in the United States and directly to cardiac centers and hospitals worldwide. Headquartered in Framingham, Massachusetts, HeartWare is committed to improving the quality of life for patients suffering from severe heart conditions.

Bionomics Limited is a clinical-stage biopharmaceutical company based in Thebarton, Australia, specializing in the discovery and development of innovative therapeutics for central nervous system disorders and cancer. The company's portfolio includes several drug candidates, with its lead product, BNC210, a negative allosteric modulator aimed at treating anxiety, panic, agitation, and post-traumatic stress disorder, having completed a phase 2 clinical trial. Additionally, Bionomics is developing BNC375, targeting cognitive impairment in Alzheimer's disease, and BNC101, a monoclonal antibody that has completed phase 1 trials aimed at cancer stem cells. The company is also advancing BNC105, a vascular disrupting agent currently undergoing phase 2 trials for refractory colorectal cancer and phase 1 trials for relapsed/refractory chronic lymphocytic leukemia. Bionomics further enhances its capabilities through the ionX platform, which integrates genomics discoveries and technologies. Founded in 1996, the company has established strategic partnerships to bolster its research and development efforts.

Peplin is a development-stage specialty pharmaceutical company dedicated to advancing medical dermatology products. The company focuses on PEP005, a compound derived from Euphorbia peplus, which is utilized in its lead product, a patient-applied topical gel currently in Phase III clinical trials for the treatment of actinic keratosis. Additionally, Peplin is developing a physician-applied topical gel for superficial basal cell carcinoma, also based on PEP005. The active ingredient in both products is a small molecule extracted and purified from the sap of Euphorbia peplus. Peplin's commitment to addressing skin disorders is further underscored by its acquisition of Neosil, Inc., a dermatology-focused company, before eventually being acquired by LEO Pharma A/S.

Arana Therapeutics is a biopharmaceutical company dedicated to developing next-generation antibody-based drugs targeting inflammatory diseases and cancer. With a focus on innovative biotechnology solutions, the company specializes in creating antibody and peptide products aimed at addressing significant medical needs in these areas. Through its research and development efforts, Arana Therapeutics strives to advance treatment options and improve patient outcomes in the fields of oncology and inflammation-related conditions.

Acrux Limited is a pharmaceutical company based in West Melbourne, Australia, specializing in the development and commercialization of generic and specialty topical pharmaceuticals. Founded in 1998, Acrux focuses on innovative drug delivery systems that administer medications through the skin. Its product offerings include testosterone solutions for men with low testosterone levels, as well as estradiol sprays for women experiencing menopausal flushes, marketed under the Evamist and Lenzetto brand names. Acrux is advancing a diverse product pipeline aimed at treating hormonal deficiencies, pain, central nervous system disorders, and contraceptive needs. The company has completed numerous human clinical trials with its lead product, Evamist, nearing the end of a phase 3 trial in the United States. With a global presence across Australia, the United States, Germany, and other countries, Acrux aims to provide affordable and effective pharmaceutical solutions through its robust technical and clinical expertise.

Nexvet Australia Pty Ltd is a biopharmaceutical company based in Melbourne, Australia, specializing in the development of biological therapies for companion animals. Founded in 2010, Nexvet focuses on creating species-specific monoclonal antibodies to address chronic pain, immune oncology, chronic inflammation, and allergies in pets. The company's key products include Ranevetmab and Frunevetmab, which target nerve growth factor to alleviate pain associated with osteoarthritis in dogs and degenerative joint disease in cats, respectively. Additionally, Nexvet is developing NV-03, a monoclonal antibody for chronic joint pain in horses. Utilizing a unique technology called PETisation, Nexvet customizes therapies to specific species, enhancing the effectiveness and safety of treatments while minimizing immune responses. As a subsidiary of Zoetis Inc., Nexvet aims to transform animal medicine by collaborating with global partners in veterinary and human health to advance its innovative pipeline.

AmpliPhi Biosciences is a biopharmaceutical company that specializes in developing bacteriophage-based therapies for bacterial infections. By utilizing naturally occurring viruses known as bacteriophages, the company aims to address various bacterial infections, particularly those caused by drug-resistant strains prevalent in hospital environments. AmpliPhi has established a drug development and manufacturing platform that enables the rapid creation and production of multiple phage-based therapies. The company’s initial focus is on treating acute and chronic infections affecting the lungs, sinuses, and gastrointestinal tract. With operations in Richmond, Virginia, Colworth Science Park near London, and outside Sydney, Australia, AmpliPhi is committed to advancing its pipeline of phage therapies to effectively combat targeted bacterial diseases.

Alchemia Limited is an Australian biopharmaceutical company that specializes in developing innovative therapies. It has an FDA-approved drug, Fondaparinux sodium, and a late-stage oncology product pipeline based on its proprietary HyACT platform. Additionally, the company leverages its chemistry expertise through its drug discovery platform, VAST®, to advance its portfolio of therapeutic candidates. Alchemia's focus on biopharmaceuticals positions it at the forefront of medical innovation, aiming to address significant healthcare needs through its research and development efforts.

Adherium Limited is a developer and manufacturer of digital health technologies focused on improving medication adherence in patients with chronic diseases. The company, founded in 2001 and headquartered in Auckland, New Zealand, offers Hailie, a solution specifically designed for asthma and COPD patients. Hailie includes Bluetooth-enabled sensors that attach to existing inhalers, capturing and transmitting usage data to patients' smartphones, complemented by a mobile app that allows users, caregivers, and healthcare professionals to track adherence, set reminders, and gain insights into medication usage. Adherium's solutions cater to a diverse range of stakeholders, including patients, pharmaceutical companies, healthcare providers, and contract research organizations. The company has established collaborations, such as with HGE Health, aimed at enhancing chronic obstructive pulmonary disease management.

SeaDragon Limited is a New Zealand-based company specializing in the manufacture and marketing of refined fish oils, operating from its facility in Nelson. Established in 1986, the company processes fish oils into high-quality marine bioactive compounds and offers Omega-3 and Omega-2 fish oil products. Its Omega-3 products are primarily derived from tuna and marine-farmed salmon, while Omega-2 can be sourced from both animal and vegetable origins. SeaDragon serves various industries, including health supplement manufacturing, cosmetics, nutraceuticals, pharmaceuticals, and lubrication, providing refined oils that meet rigorous quality standards.

Avita Medical Inc. is a commercial-stage regenerative tissue company headquartered in Valencia, California, specializing in innovative treatment solutions for burn injuries, chronic wounds, and dermatological conditions. The company leverages its proprietary technology to harness the regenerative properties of a patient’s own skin, with its lead product being the RECELL System. This device allows healthcare professionals to create a suspension of Spray-On Skin cells from a small sample of the patient's skin, facilitating the treatment of acute thermal burns in adults. Avita is currently focusing its efforts on the U.S. market, where the RECELL System is being rolled out across approximately 136 burn centers, while also exploring clinical trials for expanded indications, including pediatric applications and soft-tissue reconstruction. The company has established research collaborations with various institutions to advance its development initiatives, including potential treatments for conditions like epidermolysis bullosa and skin rejuvenation.

Millenium Biologix Corporation is a biomedical company based in Kingston, Canada, operating primarily in the United States and Europe. Founded in 1986, the company specializes in the development and commercialization of implantable medical devices and products aimed at skeletal tissue regeneration for orthopedic applications. Among its offerings is Skelite, a synthetic bone graft designed for healing and replacement purposes. Additionally, Millenium Biologix develops Primacoll and Peptos, which are intended to stimulate bone tissue growth. The company also provides ACTES, a cell culture and tissue engineering system that automates the biological processes involved in tissue engineering.

Millenium Biologix Corporation is a biomedical company based in Kingston, Canada, operating primarily in the United States and Europe. Founded in 1986, the company specializes in the development and commercialization of implantable medical devices and products aimed at skeletal tissue regeneration for orthopedic applications. Among its offerings is Skelite, a synthetic bone graft designed for healing and replacement purposes. Additionally, Millenium Biologix develops Primacoll and Peptos, which are intended to stimulate bone tissue growth. The company also provides ACTES, a cell culture and tissue engineering system that automates the biological processes involved in tissue engineering.